miR-182-5p inhibits the release of proinflammatory cytokines, such as IL-6 and TNF-α, by targeting TLR4 (toll-like receptor 4), an intrinsic immune signaling receptor, to exert a protective effect on the side effects of liver and cerebral ischemia-reperfusion injuries, such as suppression of the inflammatory response [23, 24]. The gene discussed is TLR4; the disease is Cerebral ischemia.